Drug Profile
Ascorbic acid/bicarbonate/glutathione inhalation - Renovion
Alternative Names: ARINA-1; Bicarbonate/glutathione/ascorbic acid inhalation - Renovion; Glutathione/bicarbonate/ascorbic acid inhalation - Renovion; Inhaled L-glutathione - RenovionLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer Renovion
- Class Anti-inflammatories; Antiasthmatics; Antibronchitics; Antifibrotics; Antineoplastics; Chemoprotectants; Electrolytes; Furans; Oligopeptides; Small molecules; Sugar acids; Vitamins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Bronchiolitis obliterans
- Phase II Bronchiectasis
- Clinical Phase Unknown Chronic obstructive pulmonary disease
- No development reported Cystic fibrosis
Most Recent Events
- 01 Mar 2024 Renovion completes a phase II trial in Bronchiectasis in USA (Inhalation) (NCT05495243)
- 11 Jan 2024 Renovion completes enrolment in phase-II CLIMB trial in Bronchiectasis in USA (Inhalation) (NCT05495243)
- 03 Apr 2023 Renovion plans the phase III ALOFT trial in Bronchiolitis obliterans in USA [Inhalation,Liquid] in April 2023